Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
  • Patent number: 11911357
    Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: February 27, 2024
    Assignee: Alcresta Therapeutics, Inc.
    Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
  • Patent number: 11912769
    Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: February 27, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xavier Valencia, John P. Throup, Steven G. Nadler, Suzanne J. Suchard, Dominique Duchesne, Xiaoni Liu, Rong Shi, Diane E. Shevell, Jenny H. Xie, Marek Honczarenko
  • Patent number: 11896667
    Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: February 13, 2024
    Assignee: UCB PHARMA S.A.
    Inventor: Martyn K. Robinson
  • Patent number: 11892450
    Abstract: The invention provides assay methods of detecting plasma protease CI inhibitor (C1-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-me-diated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: February 6, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kusumam Joseph, Allen P. Kaplan
  • Patent number: 11891446
    Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: February 6, 2024
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Yi Ding, April Zhang, Maximiliano Vasquez
  • Patent number: 11884720
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: January 30, 2024
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Jonas Anlahr, Julie Bailis, Claudia Blümel, Patrick Hoffmann, Peter Kufer, Elisabeth Nahrwold, Doris Rau
  • Patent number: 11873337
    Abstract: The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: January 16, 2024
    Assignees: KYOWA KIRIN CO., LTD., KAGOSHIMA UNIVERSITY
    Inventors: Nobuaki Takahashi, Ryosuke Nakano, Sayaka Maeda, Takenao Yamada, Yuji Ito
  • Patent number: 11866500
    Abstract: Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: January 9, 2024
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xing Sun, Guoqing Cao, Changyong Yang, Lianshan Zhang, Yong Guo
  • Patent number: 11866511
    Abstract: The invention relates to anti-ganglioside GD2 antibodies that comprise an antibody variable domain and antibody constant domains, wherein the variable domain comprises a heavy and light chain variable region comprising respectively at least the CDR3 of the heavy chain variable region of antibody ch14.18 and at least the CDR3 of the light chain variable region of antibody ch14.18; and an IgA hinge and CH2 domain and to methods of treatment of subjects with a GD2 positive tumor, preferably neuroblastoma with these antibodies.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: January 9, 2024
    Assignee: TigaTX, Inc.
    Inventors: Jeanette Henrica Wilhelmina Leusen, Johannes Gerardus Maria Evers
  • Patent number: 11859002
    Abstract: The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: January 2, 2024
    Assignee: The General Hospital Corporation
    Inventor: Denise L. Faustman
  • Patent number: 11851488
    Abstract: Described herein are novel anti-CD3 antibodies conjugated to folate and uses thereof treatment of diseases or conditions that would benefit from such conjugate are provided.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: December 26, 2023
    Assignee: Ambrx, Inc.
    Inventors: Harun Rashid, Feng Tian, Marco Gymnopoulos
  • Patent number: 11839654
    Abstract: The present invention provides a method of treating a tau-mediated cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-Tau antibody and an effective amount of an OGA inhibitor.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: December 12, 2023
    Assignee: Eli Lilly and Company
    Inventors: Mansuo Lu Hayashi, Michael Carl Irizarry, Hugh Nuthall
  • Patent number: 11835531
    Abstract: An in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from the subject and the correlation of the determined level to a potential risk of sustaining an adverse event.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: December 5, 2023
    Assignee: B.R.A.H.M.S GmbH
    Inventors: Joachim Struck, S. J. L. Bakker
  • Patent number: 11834497
    Abstract: Antibodies and compositions against GLUT4 and uses thereof are provided herein.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: December 5, 2023
    Assignee: INTEGRAL MOLECULAR, INC.
    Inventors: David F. Tucker, Kimberly-Anne Mattia, Christine R. Fisher, Benjamin J. Doranz, Joseph B. Rucker
  • Patent number: 11820822
    Abstract: The present invention is based, in part, on the identification of biomarkers, and methods of modulate thereof, for sensitizing cancer cells to T cell-mediated killing. For example, the present invention, in part, comprises methods of sensitizing cancer cells in a subject afflicted with a cancer to cytotoxic T cell-mediated killing comprising administering to a subject a therapeutically effective amount of an agent that modulates the biomarker.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: November 21, 2023
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Deng Pan, Kai W. Wucherpfennig
  • Patent number: 11820820
    Abstract: An antibody capable of blocking CD47-SIRPa interaction and an application thereof.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: November 21, 2023
    Assignee: CHENGDU CONMED BIOSCIENCES CO., LTD.
    Inventors: Bo Chen, Gang Xu, Xuhong Chen, Feng Li, Boyan Zhang, Sijia Huang
  • Patent number: 11814654
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: November 14, 2023
    Assignees: Institut National de la Sante et de la Recherche Medicale, Université Paul Sabatier Toulouse III
    Inventor: Elvire Gouze
  • Patent number: 11807685
    Abstract: Disclosed is an antibody that selectively binds CD47 on tumor cells. Also disclosed is a method for treating cancer in a subject, comprising administering to the subject an effective amount of the antibody disclosed.
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: November 7, 2023
    Assignee: The UAB Research Foundation
    Inventor: Xiaoguang Margaret Liu
  • Patent number: 11773173
    Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: October 3, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Akihisa Kaneko, Yuki Iwayanagi, Hidetomo Kitamura, Yoshinobu Higuchi, Hiroaki Matsushita, Ryosuke Mihara, Yumi Yamamoto, Tomohisa Saito, Keiko Hirokawa
  • Patent number: 11767369
    Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: September 26, 2023
    Assignee: MedImmune, LLC
    Inventors: Ping Tsui, Martin Borrok, William Dall'Acqua, Yanli Wu, Nurten Beyaz-Kavuncu
  • Patent number: 11752205
    Abstract: A vaccine vector comprising a first polynucleotide encoding the antigenic polypeptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or any combination thereof.
    Type: Grant
    Filed: September 20, 2022
    Date of Patent: September 12, 2023
    Inventors: Sherryll Layton, Jeffrey W. Hall
  • Patent number: 11739441
    Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain comprising an alpha chain variable domain and a beta chain comprising a beta chain variable domain and the library comprises more than one TRAV gene product and/or more than one TRBV gene product, wherein the beta chain variable domain does not comprise one or more of a TRBV5-1, 5-3, 5-4, 5-5, 5-6, 5-7 or 5-8 gene product and wherein the plurality of TCRs do not consist essentially of TCRs comprising a TRAV12-2 gene product from a natural repertoire and a TRBV6 gene product from a natural repertoire and TCRs comprising a TRAV21 gene product from a natural repertoire and a TRBV6 gene product from a natural repertoire.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: August 29, 2023
    Assignee: Immunocore Limited
    Inventors: Peter Eamon Molloy, Arsen Valeryevich Volkov, Dhaval Jaykant Sangani, Graham Anthony Hood, Chandramouli Reddy Chillakuri
  • Patent number: 11739442
    Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV12-2 gene product and the beta chain variable domain comprises a TRBV gene product.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: August 29, 2023
    Assignees: Immunocore Limited, Adaptimune Limited
    Inventors: Bent Karsten Jakobsen, Nathaniel Ross Liddy, Peter Eamon Molloy, Annelise Brigitte Vuidepot
  • Patent number: 11725045
    Abstract: Provided are antibodies or antigen binding polypeptides characterized by the ability to neutralize respiratory syncytial virus (RSV). Specifically, the antibodies or antigen binding polypeptides are characterized by high affinity binding to RSV fusion glycoprotein (RSVF). Further provided are methods for their identification, isolation, generation, preparation, and use, as well as the heavy chain and light chain sequences of the antibodies provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: August 15, 2023
    Assignee: Mapp Biopharmaceutical, Inc.
    Inventor: Laura M. Walker
  • Patent number: 11725052
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: August 15, 2023
    Assignee: Cephalon LLC
    Inventors: Anna Mikaela Bracken, Adam Clarke, Bridget A. Cooksey, Anthony Gerard Doyle, Mark Terence Liddament, Matthew Pollard, Lynn Poulton, Anna Maria Matilda Quigley, Julia Rozenfeld, Marta Szabat
  • Patent number: 11708600
    Abstract: Differential expression of long non-coding RNAs (lncRNAs) and enhancer RNAs (eRNAs) are used to diagnose diseases including neurological diseases, inflammatory diseases, rheumatic diseases, and autoimmune diseases. Machine learning systems are used to identify lncRNAs or eRNAs having differential expression correlated with certain disease states.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: July 25, 2023
    Assignee: DECODE HEALTH, INC.
    Inventor: Charles Floyd Spurlock, III
  • Patent number: 11708419
    Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: July 25, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Richard Jansson, Vineet Kumar
  • Patent number: 11708420
    Abstract: The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: July 25, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Richard Jansson, Vineet Kumar
  • Patent number: 11702642
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: July 18, 2023
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III
    Inventor: Elvire Gouze
  • Patent number: 11697680
    Abstract: The present invention relates to antigen-binding molecules, preferably antibodies or antigen-binding fragments thereof, that specifically bind to a GP73, or to an antigenic portion thereof, wherein the antigen-binding molecule binds to an epitope within the extracellular part of GP73 that is internalized into a cell usually subsequent to proteolytic cleavage. The invention further relates to immunoconjugates comprising the antigen-binding molecules, in particular the anti-GP73 antibodies, or antigen-binding fragments thereof. The antigen-binding molecules and immunoconjugates of the invention may be administered alone, as a therapeutic conjugate or in combination with other naked antibodies, or with therapeutic agents, or with other immunoconjugates or as a diagnostic conjugate. The present invention also relates to nucleotide sequences encoding anti GP73 antibodies, and immunoconjugates, vectors and host cells containing the nucleotide sequences, and methods of making anti-GP73-antibodies.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: July 11, 2023
    Assignee: CUREAB GMBH
    Inventors: Frank Stenner-Liewen, Norbert Markuly, Heike Liewen
  • Patent number: 11692035
    Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: July 4, 2023
    Assignee: Arch Oncology, Inc.
    Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
  • Patent number: 11690912
    Abstract: Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 4, 2023
    Assignee: Abcentra, LLC
    Inventors: Bertrand C. Liang, Stacey Ruiz, Christopher John Farina
  • Patent number: 11690919
    Abstract: Endolysosomal targeting conjugates that are engineered to deliver cargo molecules such as cytotoxic drugs or imaging labels with improved efficiency to late endosomes and/or lysosomes in target cells such as tumor cells are described. The endolysosomal targeting conjugate includes a targeting component and a cargo component. The targeting component is configured to bind to a cell surface molecule of a target cell and the cargo component includes a cargo molecule. The targeting component and the cargo component may be fused by a covalent bond or associated by a non-covalent bond. The targeting component may bind to the cell surface molecule or the cargo component with higher affinity in the extracellular space than in an endolysosomal compartment of the target cell.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: July 4, 2023
    Assignees: The Texas A&M University System, Board of Regents of the University of Texas System
    Inventors: Elizabeth Sally Ward Ober, Raimund Johannes Ober, Jeffrey Che-Wei Kang, Wei Sun, Ran Li
  • Patent number: 11680104
    Abstract: Antibodies, or antigen-binding fragments thereof, that bind to Lymphocyte-activation gene-3 (LAG-3) are described, in particular antibodies, or antigen-binding fragments thereof, that are agonists of LAG-3. The antibodies bind to LAG-3 and inhibit antigen-induced CD4+ and/or CD8+ T cell proliferation, or antigen-induced CD4+ and/or CD8+ T cell activation. The antibodies may be used as medicaments, in particular for the treatment of conditions associated with proliferation and/or activation of CD4+ and/or CD8+ T cells, such as inflammatory and autoimmune disorders.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 20, 2023
    Assignee: IMMUTEP S.A.S.
    Inventors: Frédéric Triebel, Chrystelle Brignone
  • Patent number: 11667726
    Abstract: It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: June 6, 2023
    Assignee: Brown University
    Inventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee
  • Patent number: 11661449
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: May 30, 2023
    Assignee: MedImmune Limited
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • Patent number: 11642394
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: May 9, 2023
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Rajasekhar Naga Venkata Sai Suragani
  • Patent number: 11634501
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: April 25, 2023
    Assignee: OncoResponse, Inc.
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Peter Probst, Tyrel T. Smith, Mark E. Branum, Randi M. Simmons
  • Patent number: 11634432
    Abstract: The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease, such as Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: April 25, 2023
    Assignee: AEOVIAN PHARMACEUTICALS, INC.
    Inventor: John Kincaid
  • Patent number: 11623917
    Abstract: The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: April 11, 2023
    Assignee: Ontogenesis, LLC
    Inventor: Gerald Horn
  • Patent number: 11613564
    Abstract: Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric/gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRP? D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 28, 2023
    Assignee: ALX Oncology Inc.
    Inventors: Jaume Pons, Hong Wan, Sophia Randolph
  • Patent number: 11596683
    Abstract: Engineered Influenza polynucleotides, viruses, vaccines, and methods of making and using the same are provided. More specifically, the present inventors have developed replication competent engineered influenza viruses having, for example, a modified segment 4 and/or segment 6 that include at least one additional polynucleotide encoding a heterologous polypeptide.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: March 7, 2023
    Assignee: Duke University
    Inventors: Nicholas Scott Heaton, Alfred Theodore Harding, Brook Elizabeth Heaton
  • Patent number: 11578137
    Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: February 14, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Wenchao Song, Sayaka Sato, Takashi Miwa, Damodar Gullipalli
  • Patent number: 11564987
    Abstract: The present invention concerns a method for treating triple-negative breast cancer (TNBC) in an individual, and/or for inducing an immune response to HER2/neu in an individual with a triple-negative breast cancer expressing low levels of HER2/neu, the method comprising administering to the individual: (a) an effective amount of trastuzumab, or derivative thereof; and (b) an effective amount of nelipepimut-S, or variant thereof, optionally with an immunological adjuvant. Preferably, the method includes a preparatory or priming phase comprising a frequency and duration of trastuzumab or trastuzumab derivative administration sufficient to substantially increase the major histocompatibility complex (MHC)-mediated presentation of HER2 peptide fragments to the patient immune system. The invention also includes medicaments and kits for treating TNBC in an individual, and/or for inducing an immune response to HER2/neu in an individual with a TNBC expressing HER2/neu.
    Type: Grant
    Filed: October 19, 2019
    Date of Patent: January 31, 2023
    Assignee: SLSG LIMITED LLC
    Inventors: George E. Peoples, Angelos M. Stergiou, Nicholas J. Sarlis
  • Patent number: 11566080
    Abstract: The present invention relates to immunoglobulins that bind IgE and Fc?RIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: January 31, 2023
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Seung Y. Chu, Holly M. Horton, Matthew J. Bernett
  • Patent number: 11567077
    Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: January 31, 2023
    Assignee: Oklahoma Medical Research Foundation
    Inventor: Kenneth Smith
  • Patent number: 11560432
    Abstract: Phycoerythrin (PE) and peptide:MHCII (p:MHCII) reactive monoclonal antibodies; methods to generate monoclonal antibodies including, for example, peptide:MHC (p:MHC) reactive monoclonal antibodies; compositions including monoclonal antibodies; and uses thereof.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: January 24, 2023
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Brian T. Fife, Justin A. Spanier, Marc K. Jenkins, Justin J. Taylor
  • Patent number: 11560421
    Abstract: The present invention provides a new antibody against ECSA type Chikungunya virus, WA type Chikungunya virus, and Asian type Chikungunya virus or an antigen-binding fragment of the antibody. The antibody against Chikungunya virus or the antigen-binding fragment of the antibody of the present invention includes a heavy chain variable region or a heavy chain (1), (2), or (3) and a light chain variable region or a light chain (4).
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 24, 2023
    Assignees: Osaka University, Mahidol University
    Inventors: Tatsuo Shioda, Emi Nakayama, Tadahiro Sasaki, Orapim Puiprom, Aekkachai Tuekprakhon, Pornsawan Leaungwutiwong, Natthanej Luplertlop
  • Patent number: 11547739
    Abstract: The present disclosure relates to methods and compositions useful for initiating and propagating ICOS-mediated signaling. In particular, the present disclosure provides three peptide motifs which promote ICOS binding and whose ablation leads to modulated ICOS signaling and modulated signaling mediated by TBK1, IRF4, IKK?, or TBKBP1. The binding of these peptide motifs or the addition of such motifs as co-stimulatory agents leads to modulated immune responses, and provides new and unexpected therapies for neurodegenerative, autoimmune, metabolic, cancer inflammatory, or immunodeficiency conditions, diseases, or disorders.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: January 10, 2023
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Amnon Altman, Kok-Fai Kong, Shane Crotty
  • Patent number: 11529445
    Abstract: The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein bound uremic toxins from a target subject utilizing the dialysis apparatus described herein as well as methods of extracorporeal detoxification.
    Type: Grant
    Filed: September 20, 2020
    Date of Patent: December 20, 2022
    Assignee: HIBAR Microsciences LLC
    Inventor: James A. Tumlin